Thirty-two thalassemic patients with a median age of 7.7 years (range 3.4-26 years) were given a second HLA-identical related marrow transplant (BMT2) for graft failure. Four patients were in class 1 and 28 patients in classes 2 and 3. Twenty-one patients had full thalassemia recurrence (first group) and 11 patients had aplastic marrows (second group) either with or without residual donor marrow cells after the first BMT (BMT1). As conditioning regimen for BMT2 all but five patients received BUCY or CY in association with total lymphoid irradiation (TLI) and/or anti-lymphocyte globulin (ALG), whereas nine patients received a new preparative regimen with hydroxyurea, azathioprine, fludarabine before conditioning with BUCY. Twenty one of 31 evaluable patients (67.7%) had initial, and 16 (51.6%) had sustained engraftment. Ten patients (32.3%) failed to engraft. Overall and event-free survival for the entire group of patients were 49% and 33%, respectively, with a median follow-up of 4 years (range 0.6-14 years) for surviving patients. Event-free survival was higher in the second group of patients compared with the first group (41% vs 29%). The second group of patients appeared to have less graft failure compared with the first group (30% vs 63%; P = 0.1). Transplant-related mortality was 28%. A linear stepwise regression analysis revealed that occurrence of graft failure within 60 days after BMT1 (P = 0.04) and absence of residual donor marrow cells (P = 0.009) predicted for graft failure following BMT2, whereas the occurrence of graft failure after 60 days (P = 0.03) had a positive influence on survival following BMT2. The incidence of grade у2 acute GVHD was low (14%). Eight of nine patients who received the new preparative regimen are alive, four without thalassemia. This study shows that BMT2 can be an effective therapy for a proportion of patients with poor survival expectancies despite conventional treatment.
Currently, the only curative treatment for thalassemia is bone marrow transplantation. [1] [2] [3] Graft failure owing to rejection and other causes is one of the more common obstacles to successful marrow transplantation, especially in the non-malignant BMT setting. Unlike the situation with hematological malignancies, patients with non-malignant diseases such as aplastic anemia and thalassemia have an increased risk of graft failure after BMT. The incidence of rejection after BMT for thalassemia varies from 7% (in risk class 1 and class 2 patients) to 22% (in class 3 patients), 4, 5 while its incidence in adult patients is low, 4%. 6 In class 3 patients analysis of rejection has revealed that patients who received less than 100 transfusions, regimens containing less than 200 mg/kg CY and who showed elevated aspartate aminotransferase had an increased rate of rejection. 5 In patients given HLA-identical related marrow transplants for thalassemia, graft failure is usually accompanied by autologous recovery of the thalassemic marrow. [3] [4] [5] However, in a small group of patients graft failure may not be accompanied by thalassemia recurrence after marrow transplantation, which is a life-threatening situation.
Two types of graft failure, primary (without evidence of engraftment or hematologic recovery of donor cells) and late (losing the graft with autologous recovery or re-occurrence of aplastic marrow), have been recognized in patients with aplastic anemia. 7 Graft failure may be immunologically mediated (graft rejection), or related to a low stem cell inoculum, cytomegalovirus infection, GVHD, drug toxicity, leukemic relapse or other causes. 8 Treatment for graft rejection or failure may be supportive care or second marrow transplant. Therapy with cytokines has improved the outcome of patients with graft failure accompanied by neutropenia. However, results of either cytokine therapy or second transplant are poor. 8, 9 For patients with primary graft failure accompanied by an aplastic marrow who are unresponsive to cytokine therapy, second marrow transplantation is the only salvage approach.
Although conventional treatment has dramatically improved survival and quality of life in patients with thalassemia, this remains a progressive disease with therapyrelated complications progressing with time. Bone marrow transplantation today is the only curative therapy that allows patients with thalassemia to lead a normal life. Thus, patients with thalassemia who experience graft failure after BMT should be offered a second transplant to cure their disease. Despite a high rejection rate, especially in inad-equately iron-chelated thalassemic patients with liver damage, there are few reports of second transplants for thalassemia. 10, 11 In a preliminary study we analyzed the results of second marrow transplantation for thalassemia. 12 In the present retrospective study we have analyzed the outcome of second BMT in 32 patients who developed graft failure after a first transplant for thalassemia. The objectives of this study were: (1) to examine survival and graft failure in patients after a second BMT; and (2) to identify factors that predispose patients to graft failure after a second BMT.
Patients and methods

Patients
From October 1982 to November 1998, 32 patients with thalassemia received a second HLA-identical related marrow transplant (BMT2) for graft failure. One of these received a third transplant for primary graft failure after BMT2 from her haploidentical mother. Another patient received a granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cell boost for graft failure following BMT2 without signs of re-engraftment. Seven patients received their first transplant (BMT1) elsewhere. Characteristics of these 32 patients are shown in Table 1 . There were 14 males and 18 females with a median age of 7.7 years (range 3.4-26 years). Four patients were in class 1, 14 in class 2 and 14 in class 3. Marrow donors and recipients were HLA-A, HLA-B, HLA-C and DR identical siblings in 27 patients, parents in four patients and a cousin in one patient. Mixed lymphocyte cultures were mutually nonreactive in all patients. All but four patients received Table 1 Characteristics of the patients before BMT1 and BMT2 bone marrow from the same donor. For one of these four patients the donor for BMT1 was the haploidentical mother and for BMT2 it was a HLA-identical sibling. Patients were categorized into two groups according to the outcome of graft failure after BMT1. The first group included 21 patients who had complete recovery of thalassemic marrow and were receiving conventional treatment before the second transplant. Eleven patients who developed aplasia after BMT1 were allocated to the second group.
BMT1 BMT2
Definition of graft failure
Graft failure was defined as primary or secondary failure. Primary graft failure is characterized by the absence of allogeneic recovery by day Ͼ21 with or without autologous reconstitution. Secondary graft failure was defined as early and late failure (losing the graft after transient engraftment within 60 days and after 60 days respectively). Secondary graft failure may be accompanied by thalassemia recurrence or marrow aplasia.
Conditioning regimens and GVHD prophylaxis
As conditioning regimen for BMT2 among 21 patients in the first group, three patients received BUCY only, seven BUCY and total lymphoid irradiation (TLI), two BUCY plus anti-lymphocyte globulin (ALG, Merrieux, France), and the remaining nine patients received a new preparative regimen including a cytoreductive-immunosuppressive and hypertransfusion-intensive chelation therapy before BUCY to reduce the hyperplastic bone marrow and increase immunosuppression before BMT2 (Table 2) . From day −45 to day −12 these nine patients received hydroxyurea 30 mg/kg/day, azathioprine 3 mg/kg/day along with hypertransfusions and i.v. continuous desferrioxamine 40 mg/kg/day and from day −17 to day −13 fludarabine (Fludara; Schering AG, Berlin, Germany) 20 mg/m 2 /day as outpatients. They were given BUCY beginning on day −9. Four of the second group of patients were given CY plus TLI and ALG, three BUCY in association with TLI and/or ALG, one CYTLI, one CYALG and two patients ALG only. Total lymphoid irradiation was given on day −1. The dose of radiation was 750 cGy 13 administered at 25 cGy/min in a single dose through anterior and posterior fields using a 10 MV linear accelerator. Lungs, thyroid, liver, kidneys and testicles in males were shielded. As GVHD prophylaxis class 1 and 2 patients received CsA + methylprednisolone (MP) and class 3 patients CsA + short MTX + MP as previously described. 4, 5 Acute and chronic GVHD were diagnosed according to the Seattle criteria. 14 Patients received the marrow infusion 36 h after the last dose of CY, on day 0. The median marrow cell dose infused was 3.9 × 10 8 /kg (range 1.9-8.0 × 10 8 /kg). The median interval from BMT1 to graft failure was 60 days (range 15-610 days), and the median interval from BMT1 to BMT2 was 675 days (35-3794 days) ( Table 2 ). Patients or their legal guardians signed informed consent.
Evaluation of graft status
Globin-chain synthesis of marrow and peripheral blood reticulocytes were examined by incorporation of followed by column or high-pressure liquid chromatography (HPLC). Chimerism status was studied by in situ Y chromosome hybridization of bone marrow or blood samples in sex-mismatched donor-recipient pairs and by analysis of variable number tandem repeat (VNTR) polymorphism in bone marrow and/or blood samples in sexmatched pairs.
Supportive care
Patients were maintained in strict isolation in single rooms with positive-pressure HEPA-filtered air and received oral broad spectrum nonabsorbable antibiotics. Prophylactic broad spectrum systemic antibiotics were begun on day −1 and continued until the granulocyte level exceeded 0.5 × 10 9 /l. From 1987, all patients received i.v. amphotericin B (0.3 mg/kg/day) as antifungal prophylaxis. Patients were given acyclovir (15 mg/kg/day) as herpes viruses prophylaxis (days −1 to +60) and trimethoprim/ sulfamethoxazole (5 mg/kg/day trimethoprim) before (days −9 to −1) and after BMT (2 days per week) for prophylaxis of Pneumocystis carinii. All blood products were irradiated with 30 Gy.
Statistical analysis
The endpoints were overall survival, event-free survival and graft failure or rejection. The probability of survival, event-free survival and rejection were estimated using the method of Kaplan and Meier. 15 Associations between survival, graft failure and the pre-transplant variables (age, sex mismatch, pre-transplant transfusions, serum ferritin, liver function tests, chronic active hepatitis, liver fibrosis, risk classes, spleen size, interval from first BMT to graft failure, interval between transplants, mixed chimerism, HLA serology, marrow cell dose, dose of cyclophosphamide, TLI, ALG) were tested in univariate analyses using the Pearson chi-squared statistics. Variables significant at the P Ͻ 0.1 level were assessed in stepwise linear regression analyses (backward elimination) using the Statistix statistical package. 16 This package was also used for engraftment characteristics. The results were analyzed on 31 March 1999.
Results
Patients
Four patients (12.5%) had primary and 28 patients (87.5%) had secondary graft failure following BMT1. In the first group of patients three had primary, nine had secondary early and nine had secondary late graft failure. Among the second group of patients, one had primary, two had secondary early and eight had secondary late graft failure. Detection of cytomegalovirus (CMV) was performed in eight of the second group patients with negative results in all cases.
Engraftment
Thirty-one of 32 patients were evaluable for engraftment following BMT2. One patient died (at day 13) before engraftment was evaluable. Twenty-one of 31 patients (67.7%) showed allogeneic engraftment and five of them subsequently lost their grafts with autologous reconstitution. Thus, 16 patients (51.6%) had sustained engraftment. Ten of 31 patients (32.3%) had failed to engraft. Three of four patients with primary and 13 of 28 patients with secondary graft failure occurring after BMT1 had sustained engraftment following BMT2. Two of four patients given BMT2 from different donors had sustained engraftment. Nine of the first group (42.8%) and seven of 10 evaluable for engraftment patients of the second group (70%) had sustained engraftment after BMT2 (P = 0.09). The median times to granulocyte count of Ͼ0.5 × 10 9 /l and platelet count of Ͼ20 × 10 9 /l were comparable after BMT1 and BMT2 ( Table 2) .
Pattern of graft failure after BMT2
In the first group seven patients developed primary, three patients secondary early and two patients secondary late failure. Three patients in the second group had primary graft failure. Three of 10 patients with primary graft failure had persistent aplasia, whereas seven patients had full thalassemia recurrence. All five patients with secondary graft failure had complete regrowth of thalassemic marrow.
GVHD
One of 27 evaluable patients after BMT1 developed grade 2 acute GVHD which resolved completely before graft failure had occurred. Chimerism study in this patient showed no residual donor cells. After BMT2 three of 21 evaluable patients (14%) developed grade у2 acute GVHD. Only one of 11 evaluable patients developed moderate chronic GVHD.
Survival and graft failure
Overall and event-free survival for the entire group of patients are shown in Figure 1 . Event-free survival was 37% at 2 years and 33% at 13 years with a median followup for surviving patients of 4 years (range 0.6 to 14 years). The probability of graft failure in all patients was 42%. The probability of event-free survival was higher (41%) in the second group of patients as compared to the first group (29%) (Figures 2 and 3) . The probability of graft failure was 30% in the second group and 63% in the first group of patients (P = 0.1). Eleven of 17 patients (64.7%) who developed graft failure within 60 days, and four of 14 patients (33%) developing graft failure over 60 days after BMT1 had graft failure following BMT2 (P = 0.04). Overall and event-free survival after BMT2 were better in patients who had graft failure over 60 days compared with patients who developed graft failure within 60 days following BMT1 (85.7% and 52.9% vs 57.1% and 17.6%, respectively; P = 0.05 for overall survival and P = 0.02 for eventfree survival). Two of four patients who developed primary and nine of 28 patients who had secondary graft failure after BMT1 are surviving without thalassemia following BMT2.
Univariate analyses showed that the occurrence of graft failure within 60 days (vs Ͼ60 days) after BMT1 (P = 0.044) and the absence of residual donor marrow cells (vs the presence) (P = 0.010) were associated with a high incidence of graft failure following BMT2. These results were confirmed by a stepwise regression analysis with the same levels of significance. Patients who received less than 200 mg CY as conditioning therapy appeared to have more failure compared with the patients receiving 200 mg CY (75% vs 38%; P = 0.07). Univariate and stepwise regression analysis for survival showed that the occurrence of graft failure over 60 days (vs Ͻ60 days) after BMT1 (P = 0.033) had a positive influence on survival following BMT2. Factors not influential on rejection and survival after BMT2 were: age, sex mismatch, pre-transplant transfusions, serum ferritin, liver function tests, chronic active hepatitis, liver fibrosis, risk classes, spleen size, interval between BMT1 and BMT2, HLA serology, dose of cyclophosphamide and the use of TLI or ALG in conditioning regimen.
Results of BMT2 after a new conditioning regimen
Nine patients received a new preparative regimen with preconditioning cytoreductive-immunosuppressive and hypertransfusion-intensive chelating therapies. Results of BMT2 after this regimen are shown in Table 3 . Seven of nine patients had engraftment and three of them subsequently lost their grafts. Two patients developed primary graft failure and one (UPN 1287) with an aplastic marrow was given a third BMT from her haploidentical mother after conditioning with CY200 plus ALG. This patient had prompt engraftment but died of severe acute GVHD. All seven engrafted patients showed fast hematological recovery. The median times to granulocyte count (n = 7 patients) of Ͼ0.5 × 10 9 /l and to platelet count of Ͼ20 × 10 9 /l were 15 days (range 12-21 days) and 9 days (range 9-22 days), respectively. Only one patient developed moderate hemorrhagic cystitis and two patients had cytomegalovirus reactivation without clinical disease. 
Chimerism and outcome of BMT2
Twenty-seven patients had data regarding the origin of residual donor cells prior to BMT2. In six patients it was determined by conventional cytogenetic examination, and in the remaining patients by VNTR examination of DNA and/or FISH. Twenty patients had no residual donor cells, while seven patients showed persistence of cells of donor origin in bone marrow before BMT2. In the first group only one of 18 patients evaluable for chimerism (5.5%) had residual donor cells, while six of nine evaluable patients of the second group (66.6%) had residual donor cells ranging from 1% to 100% (on FISH or VNTR-DNA examinations) before BMT2. The only patient who had chiefly donor cells (100%) prior to BMT2 had a severe aplastic marrow not responsive to CsA and steroids for more than 2 months. All seven patients with residual donor cells had secondary late graft failure and sustained engraftment, whereas nine of 20 patients (45%) without donor cells had sustained engraftment following BMT2. Three of seven patients who had residual donor marrow cells are alive without thalassemia, whereas 15 of 20 patients without residual cells are alive and eight of them are free of thalassemia.
Therapy-related complications
None of the patients who received BMT2 experienced veno-occlusive disease. The incidence of infectious complications was higher in patients after BMT2 than after BMT1, but this difference was not statistically significant. Twelve patients developed bacteremia by Gram-positive and Gramnegative species after BMT1, while 18 patients developed bacterial (four patients), bacterial and/or fungal (seven patients), bacterial-fungal and/or CMV (seven patients) infections after BMT2. Five patients (15.6%) developed moderate to severe hemorrhagic cystitis, one patient moderate mucositis, and one patient gastro-intestinal hemorrhage after BMT2, while only three patients experienced therapyrelated toxicity following BMT1 (moderate mucositis, reversible liver failure and moderate to severe hemorrhagic cystitis, respectively). All patients recovered from hemorrhagic cystitis with medical (four patients) and surgical (one patient) management.
Therapy-related death
Overall, 11 patients (34%) died after BMT2. Causes of death are shown in Table 4 . Two of three patients with thalassemia recurrence died at home at 215 and 1371 days after BMT2 while receiving conventional treatment (causes unknown). The third patient died of pneumonitis. Three patients with primary graft failure died of infectious complications while suffering prolonged aplasia. Five patients died with sustained engraftment. Thus, the transplantrelated mortality was 28% (nine of 32 patients) in this series. The late death in the patient with a functioning graft occurred at day 248 after transplant secondary to Pneumocystis carinii infection.
Reinfusion of autologous bone marrow
Six patients, three with primary and two with secondary early graft failure, received autologous bone marrow stored before BMT2. One of these patients had spontaneous recovery of granulocytes, while in the remaining five patients the use of G-CSF accelerated granulocyte recovery. Autologous back-up was given to accelerate platelet recovery. Only one of six patients became platelet independent on day 46 after the autologous back-up, while the remaining five were platelet transfusion-dependent for 3-5 months after reinfusion. 
Discussion
Second bone marrow transplantation for malignant and non-malignant diseases is associated with a high morbidity and mortality. 7, 17 While for patients who have developed graft failure with an aplastic marrow unresponsive to cytokine therapy a second transplant is the only salvage treatment, the choice of a BMT2 for patients with thalassemia recurrence is always a difficult decision. Graft failure secondary to rejection is a common obstacle to successful marrow transplantation, especially in class 2 and class 3 patients. However, these are patients who have developed progressive and significant organ damage while receiving conventional treatment. Thus, even a low number of cured patients may justify second transplants, as the survival expectancies of such patients are poor in the absence of marrow transplantation. 18 Our data showed that the initial engraftment rate for entire group of patients after BMT2 was lower than it was after BMT1 (67.7% vs 87.5%; P = 0.05), perhaps due to sensitization to donor antigens after BMT1. 19 Obviously, the pattern of graft failure after BMT2 was different from that observed after BMT1 with a prevalence of primary graft failure following BMT2.
Our experience of second transplants demonstrates that a proportion of patients (33%) receiving BMT2 may be cured. We identified two groups of patients according to the outcome of graft failure after BMT1: with thalassemia recurrence and with an aplastic marrow. The probability of event-free survival was better in the second than in the first group of patients (41% vs 29%). In the present study only the occurrence of graft failure later than 60 days after BMT1 (secondary late failure) had a positive influence on survival following BMT2. Survival advantage after BMT2 given for late graft failure has also been demonstrated in patients with aplastic anemia. 20 We found that patients who developed graft failure within 60 days after BMT1 and who did not have residual marrow cells had a high incidence of graft failure following BMT2.
Our data showed that graft failure after transplant may be characterized by either the presence or absence of donor marrow cells. It has been suggested that late graft failure occurring after initially successful engraftment is presumably an immune-mediated phenomenon and may be associated with the discontinuation of CsA in some patients. 21 In our series all but two patients who developed secondary late graft failure were tapering their CsA therapy. The remaining two patients had recently discontinued CsA therapy when they developed marrow aplasia. None of these patients responded to high-dose steroids. In these patients the cause of the development of aplasia is probably immune-mediated, although other mechanisms can not be excluded. It is of interest to note that patients with residual donor marrow cells before BMT2 had 100% sustained engraftment, probably due to donor-host tolerance. 22 Despite the high success in achieving engraftment, eventfree survival in these patients was low due to high transplant-related mortality.
The success of second BMT depends in part on increased immune suppression in the preparative regimen prior to BMT2 compared to that used for the first transplant. In the present study most patients received TLI and/or ALG in addition to BUCY or CY. Storb et al 23 have reported that adding ATG to cyclophosphamide as conditioning for a second transplant for aplastic anemia increased successful engraftment. Neither the dose of CY nor the use of TLI or ALG had influence on survival or rejection after BMT2 in our study. The ideal conditioning regimen for BMT2 for thalassemia is still to be determined. We have recently adopted a new preparative regimen for class 3 patients and patients receiving a second transplant, with some encouraging results.
An increased incidence of acute and chronic GVHD after second BMT has been reported. 24 These data differ from the current study in which the rates of acute and chronic GVHD were low. This low incidence of acute GVHD may be related to the combined GVHD prophylaxis given to most of the patients in our series. On the other hand, analysis of the incidence of GVHD is made difficult by the high rate of primary graft failure after BMT2.
Moderate to severe hemorrhagic cystitis was the most frequent transplant-related toxic complication observed after BMT2, probably due to re-exposure of patients to cyclophosphamide. In the current study the most frequent cause of death was infection, mainly fungal, as has been observed in other studies. 24 Fifty-five percent of deaths occurred before 100 days after BMT2. It is important to note that, the probability of death was higher in patients with aplasia compared to patients with thalassemia recurrence. This reflects the severity of this form of graft failure associated with prolonged neutropenia and a risk of developing infections which require early intervention.
The use of cytokines has improved the outcome in patients with graft failure accompanied by neutropenia. 8, 9 An alternative therapy to accelerate myeloid recovery might be reinfusion of stored autologous bone marrow before BMT2. 25 As our patients had good myeloid recovery, we used autologous reinfusion mainly to accelerate platelet recovery. Despite autologous back-up most patients required considerable time to achieve platelet independence in this series. Taking into consideration the fact that the incidence of primary graft failure is particularly high after BMT2 and not all patients with graft failure respond to cytokines, we recommend that autologous bone marrow should be harvested and cryopreserved prior to second transplant.
These data suggest that second bone marrow transplantation can cure a proportion of patients with a poor survival expectancy on conventional treatment. The high rate of graft failure following BMT2 demonstrates that the conditioning regimens used probably did not provide sufficient immunosuppression for successful graft in nearly half of our patients. Results of the new conditioning regimen are encouraging in terms of overall survival and transplantrelated toxicity and a subsequent increase of immunosuppression in this preparative regimen may be effective in obtaining a higher cure rate.
